BANB.SW
T2Bachem Holding AG
Key Reported Metrics, Reratings Triggers & ResultsThis segment's growth is crucial as it represents the commercialization success of Bachem's core peptide and oligonucleotide Active Pharmaceutical Ingredients (
| Key reported metrics | Rerating thresholds | ||||
|---|---|---|---|---|---|
| Metric | Last period | Why it matters | What's needed for rerating | Rerating context | Earnings date |
| Commercial API Sales | +32.4% | This segment's growth is crucial as it represents the commercialization success of Bachem's core peptide and oligonucleotide Active Pharmaceutical Ingredients (APIs). It directly reflects the impact of GLP-1 drug demand and the company's ability to scale production for commercial use. | Commercial API Sales growth of 35% or higher in local currencies, aligning with or exceeding the lower end of Bachem's full-year 2026 total sales guidance of 35-45%. This would also entail beating the analyst consensus sales forecast of CHF 321.63M for Q2 2026 and providing positive updates on the ramp-up of Building K and the Sisslerfeld expansion. | Hitting this threshold matters because it directly validates Bachem's bullish investment thesis as a leading peptide API producer, demonstrating successful execution of its capacity expansion strategy (Building K, Sisslerfeld) to meet surging demand for GLP-1 and other peptide drugs. This confirms its competitive position and justifies significant capital investments, driving positive valuation and market confidence. | |
| Total Revenue | +30.2% | Total Revenue directly indicates market demand for Bachem's peptide and oligonucleotide products, especially with the rising prevalence of obesity driving GLP-1 drug demand. Strong growth signals robust business health and market share expansion. | Total Revenue growth of at least 35% year-over-year in local currencies for H1 2026, demonstrating strong progress towards the full-year 2026 guidance of 35-45% sales growth and annual sales exceeding CHF 1 billion. | Hitting a Total Revenue growth of at least 35% in local currencies matters because it validates the strong demand for Bachem's peptide APIs, aligning with the bullish GLP-1 thesis. This demonstrates successful capacity expansion and market penetration, enhancing competitive position and justifying a higher valuation by exceeding market expectations. | |
| EBITDA | +64.0% | EBITDA measures operational profitability and efficiency. Investors will watch for margin expansion or contraction, reflecting the company's ability to manage costs amidst capacity expansion and competitive pressures, which is critical for sustained growth. | For Bachem Holding AG (BANB.SW) to rerate higher, the company's EBITDA margin for the full year 2026 would need to exceed its guidance of 'low thirties' in local currencies, ideally reaching 33-35% or higher. This would demonstrate strong operational execution and effective capitalization on the robust demand for peptides and oligonucleotides, particularly within the rapidly expanding GLP-1 market. | Exceeding the EBITDA margin guidance signals Bachem's ability to convert strong market demand and expanded production capacity into superior profitability. This demonstrates operational efficiency, pricing power, and effective cost control, which are key drivers for a higher valuation in a growth industry like GLP-1 peptide production. | |